Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Voleon Capital Management LP

Voleon Capital Management LP boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 85.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,244 shares of the biopharmaceutical company’s stock after buying an additional 573 shares during the quarter. Voleon Capital Management LP’s holdings in Regeneron Pharmaceuticals were worth $789,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in REGN. GAMMA Investing LLC grew its position in Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock worth $517,291,000 after buying an additional 814,713 shares during the last quarter. Nuveen LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $343,764,000. Pacer Advisors Inc. grew its position in Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock worth $258,366,000 after buying an additional 390,374 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Regeneron Pharmaceuticals by 171.0% in the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company’s stock worth $305,311,000 after buying an additional 303,785 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Regeneron Pharmaceuticals by 30.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company’s stock worth $699,554,000 after buying an additional 226,952 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on REGN shares. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating for the company in a research note on Monday, June 9th. Citigroup reaffirmed a “buy” rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Finally, Argus lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $817.67.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of NASDAQ:REGN opened at $556.53 on Wednesday. The firm has a fifty day moving average of $563.69 and a two-hundred day moving average of $581.96. The firm has a market capitalization of $58.99 billion, a P/E ratio of 14.03, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,170.58. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the business posted $11.56 EPS. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.